Atlas Trials

A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.

Clinical trial NCT03290443 · COMPLETED

Trial details

NCT number
NCT03290443
Sponsor
Celgene
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Hepatic Impairment
Start date
2017-09-21
Primary completion
2018-10-26
Enrollment
31

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.